Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial
This report has been verified
by one or more authors of the
original publication.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2020;8(4):1 JAMA. 2020 Jan 14;323(2):130-139.What this means for my practice?
Findings suggest that intravenous osocimab doses of 0.6mg/kg or higher administered post-operatively are non-inferior to subcutaneous enoxaparin for the reduction of thromboembolic events in patients undergoing total knee arthroplasty. A pre-operative dose of 1.8mg/kg may also be superior to enoxaparin. However, it is unclear whether osocimab reduces the incidence of bleeding as it was not powered to detect differences in that outcome.
Study Summary
Eight hundred and thirteen patients scheduled for a total knee arthroplasty were randomized to receive a single post-operative dose of osocimab (0.3, 0.6, 1.2, 1.8mg/kg) or a pre-operative dose of osocimab (0.3, 1.8mg/kg) for the reduction of thromboembolic events, compared to enoxaparin or apixaban. The primary time-point was at the time of venography (approximately 10-13 days post-operation). Results revealed post-operative doses of osocimab 0.6mg/kg or higher to be non-inferior to enoxaparin for the primary outcome of composite venous thromboembolism at 10-13 days post-operation. The pre-operative 1.8mg/kg dose of osocimab was found to be superior to enoxaparin for the primary outcome.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
